Adrenocorticotropic Hormone (ACTH) Effects on Myelination in Subjects With MS

PHASE4TerminatedINTERVENTIONAL
Enrollment

15

Participants

Timeline

Start Date

June 30, 2016

Primary Completion Date

March 31, 2020

Study Completion Date

June 30, 2020

Conditions
Multiple Sclerosis
Interventions
DRUG

Adrenocorticotropic hormone (ACTH) gel (H.P. Acthar®)

"Adrenocorticotropic hormone (ACTH) gel, a long-acting formulation of the full sequence ACTH that includes other pro-opiomelanocortin (POMC) peptides, is considered an alternative to corticosteroids in the treatment of relapses (currently FDA approved for this indication).~ACTH (H.P. Acthar®) gel exerts direct anti-inflammatory and immune-modulating effects within the CNS, specifically on infiltrating macrophages and resident microglia as well as protecting mature oligodendrocytes from inflammation-related damage and excitotoxicity. These effects are mediated not only via induction of endogenous corticosteroid production but also via effects on melanocortin receptors."

Trial Locations (1)

10021

Weill Cornell Medicine, New York

Sponsors

Collaborators (1)

All Listed Sponsors
collaborator

Mallinckrodt

INDUSTRY

lead

Weill Medical College of Cornell University

OTHER